Table 1.
Characteristics of percutaneous coronary intervention cohort, 2017–2019.
| Household income | <$40,000 | $40-<$49,999 | $50-<$59,999 | $60-<$74,999 | $75-<$99,999 | ≥$100,000 | p-values |
|---|---|---|---|---|---|---|---|
| Age, mean (SD) | 69.7 (10.9) | 69.7 (10.8) | 70.3 (10.5) | 70 (10.6) | 69 (10.8) | 66.5 (11.1) | <0.0001a |
| Gender | |||||||
| Female, n (%) | 13,268 (46.5%) | 2820 (35.2%) | 2859 (33.3%) | 3151 (29.5%) | 3891 (26.9%) | 3879 (19.5%) | <0.0001b |
| Male, n (%) | 15,268 (53.5%) | 5195 (64.8%) | 5724 (66.7%) | 7527 (70.5%) | 10,561 (73.1%) | 16,020 (80.5%) | |
| Race | |||||||
| Asian, n (%) | 541 (1.9%) | 197 (2.5%) | 207 (2.4%) | 347 (3.3%) | 548 (3.8%) | 1056 (5.3%) | <0.0001b |
| Black, n (%) | 5482 (19.2%) | 1026 (12.8%) | 988 (11.5%) | 932 (8.7%) | 854 (5.9%) | 712 (3.6%) | |
| Hispanic, n (%) | 3550 (12.4%) | 1124 (14%) | 1128 (13.1%) | 1212 (11.4%) | 1357 (9.4%) | 1415 (7.1%) | |
| White, n (%) | 18,963 (66.5%) | 5668 (70.7%) | 6260 (72.9%) | 8187 (76.7%) | 11,693 (80.9%) | 16,716 (84%) | |
| Education level | |||||||
| <12th grade, n (%) | 251 (0.9%) | 69 (0.9%) | 41 (0.5%) | 33 (0.3%) | 23 (0.2%) | 1 (0%) | <0.0001b |
| Highschool Diploma, n (%) | 15,785 (55.3%) | 3733 (46.6%) | 3589 (41.8%) | 3324 (31.1%) | 2877 (19.9%) | 1324 (6.7%) | |
| <Bachelor Degree, n (%) | 11,672 (40.9%) | 3931 (49.1%) | 4585 (53.4%) | 6546 (61.3%) | 9959 (68.9%) | 11,694 (58.8%) | |
| Bachelor Degree +, n (%) | 794 (2.8%) | 269 (3.4%) | 356 (4.2%) | 763 (7.2%) | 1588 (11%) | 6870 (34.5%) | |
| Medication use | |||||||
| ≥5 medications, n (%) | 23,006 (80.6%) | 6155 (76.8%) | 6610 (77%) | 7954 (74.5%) | 10,472 (72.5%) | 13,180 (66.2%) | <0.0001b |
| Copay per 30 days, in dollars, median (Q1, Q3) | 5.8 (1.6,10.8) | 7.0 (2.5, 12.5) | 7.6 (2.92, 15) | 7.9 (3.3, 17.3) | 8 (3.3, 22.5) | 8.1 (3.3, 26.7) | <0.0001c |
| Clopidogrel, n (%) | 18,945 (66.4%) | 5249 (65.5%) | 5538 (64.5%) | 6832 (64%) | 8783 (60.8%) | 11,068 (55.6%) | <0.0001c |
| Prasugrel, n (%) | 1724 (6%) | 520 (6.5%) | 520 (6.1%) | 735 (6.9%) | 1122 (7.8%) | 1935 (9.7%) | |
| Ticagrelor, n (%) | 7823 (27.4%) | 2238 (27.9%) | 2516 (29.3%) | 3096 (29%) | 4533 (31.4%) | 6869 (34.5%) | |
| Health care utilization | |||||||
| Number of cardiology visits, median (Q1, Q3) | 3 (2, 6) | 3 (2, 6) | 3 (2, 6) | 3 (2, 6) | 3 (2, 6) | 3 (2, 6) | 0.03c |
| Number of Elixhauser comorbidities, median (Q1, 3) | 7 (5, 11) | 7 (4, 10) | 7 (4, 10) | 6 (4, 9) | 6 (3, 9) | 5 (3, 8) | <0.0001c |
| AMI>30 days prior to PCI, n (%) | 3363 (11.79%) | 917 (11.44%) | 928 (10.81%) | 1099 (10.29%) | 1315 (9.1%) | 1586 (7.97%) | <0.0001b |
| Prior CABG, n (%) | 1173 (4.11%) | 319 (3.98%) | 370 (4.31%) | 460 (4.31%) | 583 (4.03%) | 737 (3.7%) | 0.080b |
| Prior PCI, n (%) | 6519 (22.84%) | 1789 (22.32%) | 1998 (23.28%) | 2447 (22.92%) | 3118 (21.57%) | 4269 (21.45%) | 0.0003b |
| Enrollment and insurance | |||||||
| Insurance type = Medicare, n (%) | 23,307 (81.7%) | 6176 (77.1%) | 6628 (77.2%) | 7745 (72.5%) | 9574 (66.3%) | 10,199 (51.3%) | <0.0001b |
| Enrollment time, in months, following procedure, median (Q1, Q3) | 19 (11, 30) | 20 (11, 31) | 20 (12, 31) | 20 (12, 31) | 20 (12, 30) | 20 (12, 30) | <0.0001c |
a
Based on ANOVA.
b
Based on chi square test.
c
Based on Wilcoxon rank-sum test.